MWNA
KALA icon

Marshall Wace North America’s KALA BIO KALA Stock Holding History

Marshall Wace North America’s Portfolio KALA Stock Details KALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-9
Closed -$223K – 1343
2020
Q2 		$223K Buy
+9
New +$255K ﹤0.01% 1059
2017
Q4 		– Sell
-4
Closed -$244K – 1494
2017
Q3 		$244K Buy
+4
New +$219K ﹤0.01% 1156

Other funds holding KALA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace North America's KALA Position: Q3 2020 in Review

Marshall Wace North America sold out of KALA BIO (KALA) in Q3 2020, closing a stake of 9 shares — an estimated $223K sold.

Marshall Wace North America first reported a position in KALA in Q3 2017 and held it in 2 quarters. The position peaked at $244K in Q3 2017. 105 funds tracked by Wall St. Rank hold KALA as of Q3 2020.

  • Marshall Wace North America reported no remaining KALA BIO position as of Q3 2020 after selling out during the quarter.
  • Marshall Wace North America sold 9 KALA BIO shares in Q3 2020, an estimated $223K.
  • Marshall Wace North America first reported a position in KALA BIO in Q3 2017 and held it in 2 quarters.
  • Marshall Wace North America's KALA BIO position peaked at $244K in Q3 2017.
  • 105 funds tracked by Wall St. Rank held KALA BIO as of Q3 2020.

Based on Marshall Wace North America's 13F filing for Q3 2020, filed 16 Nov 2020.